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but is often unrecognized. Clinical manifestations include painful nodules, abscesses, sinus tracts, and
ropelike hypertrophic scars in the apocrine gland-bearing areas. It is a chronic disease. Severe dramatic
forms are rare. Treatment is both medical and surgical: wide-spectrum antibiotics and excisions tai-
lored to the extent of involvement. Quality of life is severely affected even in mild forms.
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Figure 1 Axillary masses ﬁstulated in the skin.
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Hidradenitis suppurativa (HS) was ﬁrst described in 1854 by a
French surgeon, Aristide Verneuil (Verneuil, 1854). HS is
diagnosed by its clinical features and its chronic nature; no lab-
oratory test or pathology ﬁndings identify it. It is deﬁned by
the presence of recurrent, painful, deep-seated, rounded nod-
ules that develop into abscesses and sinus tracts, with suppura-
tion and hypertrophic scarring of apocrine gland-bearing skin.
2. Deﬁnition
In San Francisco in March 2009, the second international
symposium organized by the Hidradenitis Suppurativa Foun-
dation adopted a consensus deﬁnition (Hidradenitis Suppura-
tiva Foundation, 2009): ‘‘HS is a chronic, inﬂammatory,
recurrent, debilitating, skin follicular disease that usually pre-
sents after puberty with painful deep-seated, inﬂamed lesions
in the apocrine gland-bearing areas of the body, most com-
monly, the axillary, inguinal, and anogenital regions’’.
3. Prevalence
Although HS is considered a rare disease, several studies re-
port a global prevalence of 1% in the general population (Nal-
di, 2006). A large French survey conﬁrmed this prevalence
(Revuz et al., 2008). The peak prevalence recorded is 4%, in
a population of young women in Denmark. It is likely due
to the higher prevalence in young adults and in women (sex ra-
tio: 1/3.3) (Jemec, 1988), conﬁrmed by clinical examination of
patients in another study (Jemec et al., 1996).
4. Risk factors
Naldi (2006) has reviewed the risk factors for HS. A case-con-
trol study of factors associated with HS in 302 patients (Revuz
et al., 2008) conﬁrmed that smoking and overweight are the
two main factors associated with HS. Because no temporal
relationship or dose effect has been demonstrated between
smoking and HS, this strong association cannot be considered
a true risk factor.
Furthermore, no speciﬁc mechanism has been shown to ex-
plain this association, and no study has documented the effect
of smoking cessation. Nonetheless, the medical community
generally accepts that smoking is the most important triggering
factor of HS.
Antiperspirant, talc, and deodorant use and depilation with
a safety razor have been ruled out as pathogenic factors (Mor-
gan and Leicester, 1982). Tight clothing may contribute to dis-
comfort and is considered a triggering factor by some authors.
5. Diagnostic criteria
According to the criteria adopted by the international sympo-
sium of the Hidradenitis Suppurativa Foundation in March
2009 (Hidradenitis Suppurativa Foundation, 2009), diagnosis
requires the presence of:
 typical lesions: deep-seated painful nodules: ‘blind boils’ in
early lesions; abscesses, draining sinuses, bridged scars, andopen ‘tombstone’ comedos in secondary lesions;
 typical topography: axillae, groin, perineal and perianal
regions, buttocks, infra- and intermammary folds; and;
 chronicity and recurrences.
All three criteria must be met to establish the diagnosis. Our
patient validates the three criteria.
6. Clinical features
Onset usually occurs after puberty, usually during the second or
third decade of life. There is frequently a long delay before diag-
nosis, particularly in mild cases: an abscess may be surgically
treated by incision, and the chronic or relapsing nature of the dis-
ease not considered at all. Moreover, general practitioners, sur-
geons, and even dermatologists frequently know very little about
this disease (Hidradenitis Sup-purativa Foundation, 2009).
The early lesions are solitary, painful nodules that may per-
sist for weeks or months without any change or with occa-
sional episodes of inﬂammation. Early isolated lesions are
not speciﬁc and are frequently considered to be boils or com-
mon abscesses. The shape of these nodules, round rather than
pointed and with no central necrosis, together with their
topography should help to differentiate them from common
boils. Their location deep in the hypodermis means they are
sometimes barely visible. They are extremely painful. Approx-
imately 50% of all patients experience subjective prodromal
symptoms, which may include burning, stinging, pain, pruri-
tus, heat, and hyperhidrosis, 12–48 h before the overt nodule
appears. The mean duration of a single painful nodule is 7–
15 days. The nodules may remain blind, i.e., fail to burst,
and either resolve spontaneously or persist as silent nodules
with inﬂammatory recurrences. Most frequently, however,
they turn into abscesses and rupture externally, draining puru-
lent material. Rupture into neighboring structures is rare.
The repetition of attacks may lead to chronic sinus forma-
tion, with intermittent release of serous, purulent, or blood-
stained discharges and frequent foul odors from anaerobic
colonization (Fig. 1). These persist for months, sometimes
years. Ulceration or pyogenic granulomas sometimes occur.
A characteristic secondary lesion is composed of bridged,
ropelike hypertrophic scars resulting from a healing process
Figure 2 Axillary sequelae of ﬁstulas.
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does not appear, surprisingly in view of the inﬂammatory
and infectious features observed (Poli et al., 2006). Pathology
specimens are usually not taken from patients with HS, as his-
topathology is not helpful for diagnostic and/or therapeutic
purposes.
7. Topography
In decreasing order of frequency, the affected sites are the
(Jemec, 1988; Hidradenitis Suppurativa Foundation, 2009;
Wortsman et al., 2009; von der Werth and Williams, 2000):
groin, including inner thighs; pubic region; scrotum or vulva;
perianal and perineal regions; armpits; inter- and submam-
mary folds, and buttocks. These locations are along the milk
lines of apocrine and mammary tissues, which have the same
embryonic origin. The groin and submammary regions are
most commonly affected in women, the buttocks and perianal
skin in men; the anal canal is usually spared. Several sites, fre-
quently symmetric, may be affected simultaneously; recur-
rences occur in and around the original site.
8. Severity grading
Severity is generally assessed by the Hurley classiﬁcation,
which was designed for a surgical approach (Canoui-Poitrine
et al., 2009) (Table 1).
Although most practitioners know only the most dramatic
picture of severe disease, the mild forms are more frequent
(von der Werth and Williams, 2000). HS is polymorphous;
its severity and course vary widely between individuals.Table 1 Hurley’s classiﬁcation.
Grade I Abscess formation, single or multiple without
sinus tracts and cicatrization
Grade II Recurrent abscess with tract formation and
cicatrization. Single or multiple, widely separated
lesions
Grade III Diﬀuse or near-diﬀuse involvement, or multiple
interconnected tracts and Abscesses across entire
area9. Quality of life
Quality of life (QOL) is profoundly impaired even in mild
cases. A study of 114 patients with HS using the Dermatology
Life Quality Index (DLQI) recorded a very high score, partic-
ularly for question 1, which measures the level of pain, itching,
and soreness (Hurley, 1989). A study of 61 HS patients using
several questionnaires showed that the impairment of QOL
in each ‘‘dimension’’ was signiﬁcantly higher (p< 0.001) than
for patients with neuroﬁbromatosis, urticaria, psoriasis, and
atopic dermatitis (Von der Werth and Jemec, 2001). This
was particularly dramatic for self-perception, daily living activ-
ities, mood state, social functioning and physical discomfort.
10. Complications
Acute infectious complications such as cellulitis or systemic
infection are very unusual. Lymphatic obstruction and lymph-
edema (Wolkenstein et al., 2007) as well as scrotal elephantia-
sis may complicate longstanding inﬂammation. In men,
squamous cell carcinoma is observed in buttock areas after
several decades of HS. It often starts in deep locations, so diag-
nosis is delayed and the prognosis usually very poor (Faye
et al., 2007).
11. Associated diseases
Association of HS with severe nodular acne (acne conglobata),
dissecting cellulitis of the scalp, and pilonidal cysts has been re-
ported. Pilonidal cysts are reported especially frequently: 30%
if both true sinuses and midline intergluteal dimples are con-
sidered (von der Werth and Williams, 2000).
Reticulate pigmentation of the ﬂexures is sometimes associ-
ated with HS. It is difﬁcult to say if this is a signiﬁcant associ-
ation, as usually people do not seek medical advice for these
pigment changes, which are discovered during examination
of the groin and armpits of HS patients (Maalouf et al., 2006).
Crohn’s disease (Canoui-Poitrine et al., 2009) is both a dif-
ferential diagnosis and an associated disease. Cutaneous Cro-
hn’s disease must be differentiated from HS in its perianal
location: the clinician must always be aware that the perianal
lesions of Crohn’s disease may mimic HS and should perform
the necessary workups. The atypical condyloma-like lesions
seen in Crohn’s disease are not observed in HS; conversely,
speciﬁc Crohn’s lesions are unusual outside the perianal re-
gion. It is nonetheless impossible to differentiate them on clin-
ical grounds only. The presence of epithelioid granulomas in
the dermis, away from the site of active inﬂammation, is sug-
gestive, but biopsies are not frequently performed in patients
with HS. When doubt persists, a colonoscopy must be per-
formed, even in the absence of overt digestive symptoms. True
associations do exist, including cases of axillary HS. Several
case reports and a few series of this association have been re-
ported (Bedlow and Morti-mer, 1996).
12. Treatment
Hurley deﬁned the 3 standard clinical stages, as we saw above
(Canoui-Poitrine et al., 2009) (Table 1). This classiﬁcation is
useful at least as a guide to choose between medical or limited
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(Hurley’s classiﬁcation), frequency of exacerbation, and on
the patient’s goal. A permanent cure can be obtained by wide
surgical excision, but this procedure should be considered only
in the case of advanced disease. Early disease, on the other
hand, may beneﬁt from medical or medical and surgical ap-
proaches, simultaneously or successively (Seksik et al., 2006).
Some patients suffer from recurrent painful nodules but
also experience periods of remission. They may beneﬁt from
various options. Topical treatments, including antiseptics
and antibiotics, are ineffective due to the depth of the lesions.
A short course of systemic antibiotics may be tried for an
acute, painful nodule, to shorten the duration of the episode
and to abort it, avoiding development into an abscess. Various
antibiotics have been used for this purpose. Amoxicil-
lin + clavulanic acid may be the most effective regimen, if it
is taken very early – within 1 h of the ﬁrst signs or premonitory
symptoms. A loading dose should be swallowed immediately
and followed by the same dose daily for the next few days. Int-
ralesional corticosteroids have been advocated. Rapid involu-
tion (12–24 h) of early lesions may be obtained (Church et al.,
1993). High doses of systemic steroids may be used to reduce
inﬂammation and pain. They can be used as an alternative
to high-dose antibiotics or together with antibiotics (Revuz,
2008).
For an abscess, medical treatment to abort it is ineffective;
the required surgical drainage (incision) procedure should not
be delayed. Incision of such an abscess is frequently performed
in the emergency department. Usually the diagnostic of HS is
missed. The incision is usually followed by packing; nursing in
the days that follow and especially the renewal of packing are
painful at the least and often a nightmare for the patient. A
limitation on the number of incisions and avoiding packing
most of the time should improve patients’ quality of life. Pack-
ing is necessary in the case of a very deep cavity, concave area,
narrow incision, or incomplete immediate evacuation. In those
cases, it should not be changed too often and should be
stopped as soon as it is dry (Sartorius et al., 2006).
Various drugs have been used on a long-term basis. Their
goal is to stop the progress of the disease, reduce the relapse
rate, and avoid pain and chronic suppuration. Due to the
probable heterogeneity of the disease, some patients may ben-
eﬁt from a drug that is useless for others.
For severely affected patients with a high level of inﬂamma-
tion, pain, and discharge, a 10-week regimen of clindamycin
and rifampicin (600 mg/day each) Fearﬁeld and Staughton,
1999; O’Malley et al., 2009; Gener et al., 2009 is very useful.
Patients at Hurley stage I or II may beneﬁt from it. A complete
remission, sometimes lasting as long as one year, is obtained in
some patients. In less severely affected patients or after the 10
weeks of clindamycin-rifampicin treatment, when inﬂamma-
tion and pain are reduced, maintenance treatment with tetracy-
cline can prevent new attacks. Metronidazole may also be
helpful, particularly in the case of foul odors. When surgery
is indicated, a course of antibiotics beforehand may be useful
to prevent infections, better delineate and identify the lesions
to be excised, and effectively downsize the area to be excised.
Cyproterone acetate at 2 mg/day, combined with estrogens
as a contraceptive pill, has been compared with a standard
birthcontrol pill; no difference was observed between the two
products (Mendonc¸a and Grifﬁths, 2006). It may thereforebe useful at very high doses (100 mg/day) in a very limited
number of patients.
Finasteride has been used in about ten female patients, with
good results reported (Hessel et al., 2009; Mortimer et al.,
1986). Dapsone has been used with good results (Joseph
et al., 2005). It must be used cautiously in view of its very seri-
ous side effects.
Only transient efﬁcacy was observed with inﬂiximab in a
series of seven patients, where only two patients had sustained
results and three had severe side effects (Farrell et al., 1999). A
case report of lethal squamous cell carcinoma after treatment
with inﬂiximab has been published (Faye et al., 2007). A pro-
spective open study of 15 patients treated with etanercept
50 mg weekly found only three responders (Kaur and Lewis,
2006). A small randomized controlled study has shown some
results despite the negative ﬁndings for the main outcome mea-
sure (Fardet et al., 2007).
Several series of patients have been treated with radiother-
apy at doses up to 8 gray. Considering the high spontaneous
cancer risk, especially for skin cancers in gluteal locations, this
potentially carcinogenic treatment should be considered with
caution (Lee et al., 2009).
Surgery (Grant et al., 2010) must be performed by an expe-
rienced surgeon, aware of the difﬁculties and failures which
may occur in HS. The proper identiﬁcation of the entire lesion
is important as remnant tissue may facilitate recurrences.
High-frequency ultrasound examination of the skin or mag-
netic resonance imaging or both may be helpful. The major ele-
ment for a good and permanent result is the mapping of sinus
tracts and ﬁstulas, usually done during the surgery.
CO2 laser excision is used in mild to moderate disease with
secondary healing. Superiority in comparison with standard
surgery is a matter for debate (Fro¨hlich et al., 2000; Lapins
and Emtestam, 2006; Lapins et al., 1994; Lapins et al., 2002).
13. Conclusion
HS is an orphan disease, not because of its rarity – for it is fre-
quent – but because physicians know too little about it. Treat-
ment is not curative, except for wide surgery, appropriate only
for very severe cases; good management, using standard well-
known treatments, is often more useful than the so-called
innovative treatments, whose risk/beneﬁt ratios are unknown
today.
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